Ichnos Glenmark Innovation (IGI), a collaboration between Glenmark Pharmaceuticals Limited and Ichnos Sciences Inc., has unveiled promising results from its Phase 1 clinical trial involving the trispecific antibody ISB 2001. The announcement was made ahead of the 66th American Society of Hematology (ASH) Annual Meeting, which is set to take place in December 2024 in […]
Glenmark Pharmaceuticals Limited (Glenmark) has announced impressive financial results for the first quarter of FY 2024-25, marked by a 6.9% increase in consolidated revenue and notable improvements in profit margins. For the quarter ending June 30, 2024, Glenmark’s consolidated revenue was ₹3,244.2 crores, up from ₹3,036.1 crores in the same period last year. EBITDA surged […]
Glenmark Pharmaceuticals Limited, a research-led, global pharmaceutical company, today released its financial results for the fourth quarter ending March 31, 2024, showcasing a solid performance across its diversified markets despite some challenges in North America. Glenmark Pharmaceuticals Financial Highlights and Performance For the fourth quarter of FY 2023-24, Glenmark reported a consolidated revenue of Rs. […]
In a significant development for Glenmark Pharmaceuticals Ltd., the company has received final approval from the United States Food & Drug Administration (U.S. FDA) for its Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%. This approval positions Glenmark to substantially penetrate a lucrative market segment currently valued at approximately $290 million in annual sales, according […]
Glenmark Pharmaceuticals Ltd. has successfully secured the final approval from the United States Food & Drug Administration (U.S. FDA) for its Apremilast Tablets in 10 mg, 20 mg, and 30 mg dosages. This approval allows Glenmark to market the generic counterpart of Amgen Inc.’s Otezla Tablets. Recent IQVIA sales figures reveal that the market for […]
Ichnos Sciences, a prominent clinical-stage biotechnology firm specializing in pioneering multispecific antibodies for oncology and under the ownership of Glenmark Pharmaceuticals, has announced a momentous worldwide licensing agreement. The deal sees Ichnos licensing its prized OX40 antagonist monoclonal antibody portfolio to Astria Therapeutics, a biopharmaceutical powerhouse dedicated to developing cutting-edge therapies for rare allergic and […]
Glenmark Pharmaceuticals (Glenmark Pharma), a research-led global pharmaceutical player, has inked a deal with Nirma Limited to divest a substantial 75% stake in its offshoot, Glenmark Life Sciences Limited (GLS), with each share pegged at INR 615/-. The overall consideration for this game-changing deal stands at an astounding INR 5,651.5 crores, after which Glenmark Pharma […]
Glenmark Pharmaceuticals Ltd., a global leader in pharmaceutical research, has secured the final nod from the U.S. Food & Drug Administration (U.S. FDA) for its Tacrolimus Ointment, 0.03%. This ointment stands as the generic counterpart to Leo Pharma AS’s Protopic Ointment, 0.03%. Marking its entry into the U.S. market, the product will be distributed by […]
Glenmark Pharmaceuticals has bagged final approval for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg from the US Food & Drug Administration (FDA). The approved product is the generic version of GlaxoSmithKline’s Compazine Tablets, 5 mg and 10 mg. Compazine is indicated for the treatment of nausea, schizophrenia, migraines, anxiety, and psychosis. Glenmark Pharmaceuticals […]
Glenmark Pharmaceuticals, through its subsidiary Glenmark Specialty, is set to begin a first-in-human, phase 1/2 clinical study of GRC 54276 in the US for the treatment of advanced solid tumors and lymphomas. This was after Glenmark Specialty’s investigational new drug (IND) application for GRC 54276 was accepted by the US Food and Drug Administration (FDA). […]